CHRS

Coherus Oncology, Inc.

A biopharmaceutical company that develops and sells immuno-oncology medicines — therapies that help the immune system find and attack cancer cells. Its flagship product, LOQTORZI, is an FDA-approved treatment for nasopharyngeal carcinoma, a type of head and neck cancer. Founded in 2010 by a longtime Amgen executive, the company spent over a decade as a maker of lower-cost biosimilar drugs before selling those products and renaming itself Coherus Oncology in 2025 to focus purely on cancer treatments. The name "Coherus" evokes the word "cohere," reflecting the company's focus on combining different therapies to fight cancer.

Recent Activity

Show $

2016Q4

1 sell

ArrowMark PartnersEXIT

-2.3K shares

ArrowMark PartnersEXIT

-2.3K shares

2016Q3

1 buy

ArrowMark PartnersNEW

+2.3K shares

ArrowMark PartnersNEW

+2.3K shares